Pharmaceuticals, Biotechnology & Life Sciences

Insider buying surge at Cue Biopharma signals confidence in a pre‑clinical milestone and partnership with Boehringer, hinting at future upside and volatility.

Pharvaris NV insider selling: CEO’s modest 23,333‑share sale amid a 10% rally signals routine portfolio management, not a bearish warning. Learn how this move reflects executive confidence and impacts investor strategy.

Pfizer insider confidence: senior execs hold 45K shares and SARs, boosting long‑term growth signals amid market volatility.

OrbiMed’s recent sell‑orders inject fresh liquidity into Adicet Bio, reflecting a strategic recalibration of institutional stakes amid rising investor caution.

Vistagen insiders issue 75,000 options, signaling long‑term confidence and a potential rebound for the biotech stock.

GRAIL CFO Freidin Aaron sells 45,806 shares in April 2026: a routine tax‑cover move amid market volatility, not a bearish signal for investors.

Alterity Therapeutics CFO’s new option purchase signals a quiet shift in management outlook, hinting at potential upside as the company nears clinical milestones.

Relay Therapeutics CFO’s disciplined 10b5‑1 sale signals confidence amid a 52‑week high—investors can gauge future upside by tracking insider trades and earnings.

Insider option grants at Vistagen Therapeutics signal executives’ confidence in the stock’s future value, hinting at potential upside amid clinical milestones.

Investor alert: CEO Robert Ragusa’s $49.92 block sale of 123K GRAIL shares raises questions—tax‑covering or warning of short‑term volatility? Click to see what insiders mean.